CytoMed Therapeutics Ltd News - GDTC

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial

SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed...

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/mee...

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

glenn1919 1 month ago

GDTX..................................https://stockcharts.com/h-sc/ui?s=GDTX&p=W&b=5&g=0&id=p86431144783

.................thx...............................

👍️0

tw0122 1 month ago

Above $3 at $3.04 + 32% for this low float cancer play

👍️0

Monksdream 6 months ago

GDTC under $3

👍️0

glenn1919 6 months ago

GDTC.............https://stockcharts.com/h-sc/ui?s=GDTC&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 9 months ago

Monksdream 2 years ago

GDTC gap fill candidate bears gotta love it

👍️0

Eurotradr 2 years ago

So much further to go. $10 min.

👍️0

Monksdream 2 years ago

GDTC No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

AJ Freely 2 years ago

$GDTC -Up 300% from yesterdays close
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
Current Price $9.63

👍️0

Monksdream 2 years ago

Nurse Sherry bought 100 at $7.50

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

CytoMed Therapeutics Ltd (GDTC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GDTC News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GDTC Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

CytoMed Therapeutics Ltd (GDTC) News

CytoMed Therapeutics Ltd (GDTC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GDTC News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

GDTC Discussion

Your Recent History

Go Ad-Free